The Companion Diagnostics Market was estimated at USD 6.68 billion in 2023 and is poised to reach at 17.13 billion in 2031 anticipated to expand at a compound annual growth rate approx. CAGR of 12.5% for the forecast period of 2024-2031.
In the field of personalised medicine, where therapies are customised for individual patients based on their unique traits, such as their genetic make-up or molecular profile, companion diagnostics play a critical role. Companion Diagnostics helps to optimise the use of costly medications, enhance treatment results, and prevent unneeded side effects by identifying patients who are more likely to respond to a certain therapy.
Get more information on the Companion Diagnostics Market - Request Sample Report
By locating particular biomarkers or genetic variants linked to the illness or therapy response, companion diagnostics can be created. These biomarkers may be genes, proteins, or other quantifiable signs that offer important details about the patient's illness condition or propensity to respond to a certain medication. Health regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are in charge of monitoring the development and approval of companion diagnostics. To ensure Companion Diagnostics' dependability and clinical value, regulatory bodies assess its safety, efficacy, and analytical validity. Pharmaceutical and diagnostic businesses frequently work together on the development and commercialization of Companion Diagnostics. The treatment drugs are supplied by pharmaceutical firms, while the companion diagnostic tests are developed and validated by diagnostic businesses. By working together, the medicine and diagnostic test are exploited to their fullest potential for patient benefit. Numerous medical specialities, such as cancer, infectious diseases, cardiovascular disorders, neurology, and others, employ companion diagnostics. Companion Diagnostics, for instance, can find certain mutations or biomarkers in oncology that show a patient's receptivity to various cancer therapy.
DRIVERS
Individualized Medicine The prevalence of complex diseases is rising.
Regulatory Assistance.
By enabling tailored therapy, companion diagnostics are essential in the age of personalized medicine. The introduction of companion diagnostics is being driven by the rising desire for individualized treatment plans. Accurate diagnostic tools are required due to the growth in complicated illnesses including cancer, genetic abnormalities, and infectious infections. Companion diagnostics provide accurate illness characterization and diagnosis, enabling more individualized therapy choices. Companion diagnostics are valuable, and regulatory organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established rules for their creation and approval. Positive regulatory backing promotes market expansion.
RESTRAIN
High development costs, difficulties with reimbursement, and a lack of companion diagnostic biomarkers.
Companion diagnostic development requires extensive research, development, and validation procedures. Companion diagnostic tests may not be as accessible or affordable due to these high expenses. varied healthcare systems and geographical areas have varied companion diagnostics reimbursement and coverage regulations. Market expansion may be hampered by the absence of standardized reimbursement mechanisms and reimbursement uncertainty. It might be difficult to find and validate appropriate biomarkers for companion diagnostics. The creation and use of companion diagnostics are directly impacted by the availability of validated biomarkers.
OPPORTUNITY
Emerging Technologies.
Technology Advances Growing Collaborations.
Beyond cancer, additional treatment fields including cardiovascular disease, infectious illnesses, and neurological disorders are now using companion diagnostics. This diversity offers fresh chances to grow the industry. Technology developments like liquid biopsy, digital pathology, and next-generation sequencing (NGS) are improving the efficiency and precision of companion diagnostics. These developments pave the way for increased clinical usefulness and diagnostic precision. The development of companion diagnostics is being promoted by increased cooperation between pharmaceutical firms, diagnostic manufacturers, and research organizations. The acceptance and marketing of companion diagnostic items can be sped up by collaborative initiatives.
CHALLENGES
Market Access Barriers Complex Regulatory Environment.
Adoption and Education of Doctors.
Companion diagnostics' regulatory environment might be complicated and dynamic. Developers and manufacturers face difficulties adhering to regulatory criteria, including clinical validation and securing required approvals. Due to varied payment practices, intellectual property rights, and market competitiveness, companion diagnostics confront challenges to market availability. Strategic market entry strategy is required to overcome these obstacles. Companion diagnostics' successful incorporation into clinical practice depends heavily on physician knowledge, comprehension, and uptake. To make healthcare personnel aware of the advantages and practicality of companion diagnostics, education programmers are required.
Regulatory agencies and systems may experience disruptions or adjustments during times of conflict. This may have an effect on Companion Diagnostics' clearance and approval, as well as the application of pertinent rules and regulations. The market entry of novel diagnostic tests might be slowed down by regulatory delays or revisions.
Priorities in healthcare frequently shift towards emergency treatment and essential healthcare services during times of conflict and humanitarian catastrophes. Companion Diagnostics, which are often employed in personalised medicine and targeted therapeutics, could attract less money and attention than urgent medical need.
IMPACT OF ECONOMIC SLOWDOWN
It's important to keep in mind that a recession's impact on the market for companion diagnostics may change based on the length and severity of the economic downturn in various geographic regions. Furthermore, during a downturn, changes in healthcare technology, lower healthcare prices, a delay in integrating new technology, a reduction in access to healthcare, the impact of the pharmaceutical sector on the structure of the healthcare system, and governmental restrictions can all have an impact on market dynamics. The market for companion diagnostics is expanding at an accelerated rate due to factors such as the growing use of personalised medications, a rise in adverse drug reactions (ADRs), and an increase in the number of unmet requirements for cancer treatment. The business is seeing favourable expansion thanks to rising healthcare costs worldwide and improvements in diagnostic technology.
Assays, Kits & Reagents
Instruments/systems
Software & Services
Assays, Kits & Reagents segment holds the largest share due to the wide variety of tests available and their use across different areas of medicine.
Polymerase Chain Reaction
Next-generation Sequencing
In Situ Hybridization
Immunohistochemistry
Other Technologies
PCR technology dominates due to its ease of use, readily available kits, and ability to detect specific gene mutations.
Cancer
Lung Cancer
Breast Cancer
Blood Cancer
Colorectal Cancer
Other Cancer Types
Neurological Disorders
Cardiovascular Diseases
Infectious Diseases
Other Indications
Cancer segment is the largest due to the increasing use of companion diagnostics in personalized cancer treatments and the importance of biomarkers in cancer diagnosis.
Tissue Samples
Blood Samples
Other Sample Types
Tissue samples are preferred because they provide a more comprehensive view of genetic mutations and biomarkers for better treatment decisions.
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
Other End Users
Pharmaceutical & Biotechnology Companies and Reference Laboratories segment holds the largest share due to the growing importance of companion diagnostics in drug development and the need for accurate testing.
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
North America:
In 2023, North America brought in USD 2.35 billion. The domination of the region is ascribed to a greater frequency of cancer and other chronic diseases as well as a rise in the use of sophisticated CDx tests in the area.
Europe:
On the other hand, it is expected that in terms of revenue, Europe would rank second internationally in 2023. The expansion of cooperation between local pharmaceutical firms and companion diagnostic manufacturers is credited with the region's success.
Need any customization research on Companion Diagnostics Market - Enquire Now
The major key players are Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories, Abbott, Myriad Genetics, Inc., bioMérieux SA, Invivoscribe, Inc., and others.
August 2023: Agilent Technologies (US) received European certification for their companion diagnostic assay.
March 2023: Roche (Switzerland) secured FDA approval for an expanded use of their diagnostic assay to identify lung cancer patients suitable for a specific therapy.
August 2023: QIAGEN (Netherlands) gained FDA approval for their companion diagnostic test for Blueprint Medicines' cancer treatment.
September 2022: Thermo Fisher (US) announced FDA approval for the first NGS-based companion diagnostic test for thyroid cancer treatment selection.
January 2021: Roche (Switzerland) launched digital pathology tools to aid in precise breast cancer diagnosis.
Agilent Technologies Inc-Company Financial Analysis
| Report Attributes | Details |
| Market Size in 2023 | US$ 6.68 Bn |
| Market Size by 2031 | US$ 17.13 Bn |
| CAGR | CAGR of 12.5% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments |
• By Product (Assays, Kits, Reagents, System, Software & Services) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories, Abbott, Myriad Genetics, Inc., bioMérieux SA, Invivoscribe, Inc., and others |
| Key Drivers | • Individualized Medicine The prevalence of complex diseases is rising. • Regulatory Assistance. |
| Market Opportunities | • Emerging Technologies. • Technology Advances Growing Collaborations. |
Ans: The CAGR Growth rate of Companion Diagnostics Market is approx. CAGR 12.5% for the forecast period of 2024-2031.
Ans: The projected market size of Companion Diagnostics USD 6.68 billion in 2023 and is poised to reach at 17.13 billion in 2031.
Ans: The major key players are Agilent Technologies, Inc., Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories, Abbott, Myriad Genetics, Inc., bioMérieux SA, Invivoscribe, Inc., and others.
Ans: The market will expand due to the rising incidence of cancer globally.
Ans: During the projected period, by product the Assays, Kits & Reagents segment holds the largest share.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Companion Diagnostics Market Segmentation, By Product & Service
9.1 Introduction
9.2 Trend Analysis
9.3 Assays, Kits & Reagents
9.4 Instruments/systems
9.5 Software & Services
10. Companion Diagnostics Market Segmentation, By Technology
10.1 Introduction
10.2 Trend Analysis
10.3 Polymerase Chain Reaction
10.4 Next-generation Sequencing
10.5 In Situ Hybridization
10.6 Immunohistochemistry
10.7 Other Technologies
11. Companion Diagnostics Market Segmentation, By Indication
11.1 Introduction
11.2 Trend Analysis
11.3 Cancer `
11.3.1 Lung Cancer
11.3.2 Breast Cancer
11.3.3 Blood Cancer
11.3.4 Colorectal Cancer
11.3.5 Other Cancer Types
11.4 Neurological Disorders
11.5 Cardiovascular Diseases
11.6 Infectious Diseases
11.7 Other Indications
12. Companion Diagnostics Market Segmentation, By Sample Type
12.1 Introduction
12.2 Trend Analysis
12.3 Tissue Samples
12.4 Blood Samples
12.5 Other Sample Types
13. Companion Diagnostics Market Segmentation, By End User
13.1 Introduction
13.2 Trend Analysis
13.3 Pharmaceutical & Biopharmaceutical Companies
13.4 Reference Laboratories
13.5 Contract Research Organizations
13.6 Other End Users
14. Regional Analysis
14.1 Introduction
14.2 North America
14.2.1 Trend Analysis
14.2.2 North America Companion Diagnostics Market By Country
14.2.3 North America Companion Diagnostics Market By Product & Service
14.2.4 North America Companion Diagnostics Market By Technology
14.2.5 North America Companion Diagnostics Market By Indication
14.2.6 North America Companion Diagnostics Market, By Sample Type
14.2.7 North America Companion Diagnostics Market, By End User
14.2.8 USA
14.2.8.1 USA Companion Diagnostics Market By Product & Service
14.2.8.2 USA Companion Diagnostics Market By Technology
14.2.8.3 USA Companion Diagnostics Market By Indication
14.2.8.4 USA Companion Diagnostics Market, By Sample Type
14.2.8.5 USA Companion Diagnostics Market, By End User
14.2.9 Canada
14.2.9.1 Canada Companion Diagnostics Market By Product & Service
14.2.9.2 Canada Companion Diagnostics Market By Technology
14.2.9.3 Canada Companion Diagnostics Market By Indication
14.2.9.4 Canada Companion Diagnostics Market, By Sample Type
14.2.9.5 Canada Companion Diagnostics Market, By End User
14.2.10 Mexico
14.2.10.1 Mexico Companion Diagnostics Market By Product & Service
14.2.10.2 Mexico Companion Diagnostics Market By Technology
14.2.10.3 Mexico Companion Diagnostics Market By Indication
14.2.10.4 Mexico Companion Diagnostics Market, By Sample Type
14.2.10.5 Mexico Companion Diagnostics Market, By End User
14.3 Europe
14.3.1 Trend Analysis
14.3.2 Eastern Europe
14.3.2.1 Eastern Europe Companion Diagnostics Market By Country
14.3.2.2 Eastern Europe Companion Diagnostics Market By Product & Service
14.3.2.3 Eastern Europe Companion Diagnostics Market By Technology
14.3.2.4 Eastern Europe Companion Diagnostics Market By Indication
14.3.2.5 Eastern Europe Companion Diagnostics Market By Sample Type
14.3.2.6 Eastern Europe Companion Diagnostics Market, By End User
14.3.2.7 Poland
14.3.2.7.1 Poland Companion Diagnostics Market By Product & Service
14.3.2.7.2 Poland Companion Diagnostics Market By Technology
14.3.2.7.3 Poland Companion Diagnostics Market By Indication
14.3.2.7.4 Poland Companion Diagnostics Market By Sample Type
14.3.2.7.5 Poland Companion Diagnostics Market, By End User
14.3.2.8 Romania
14.3.2.8.1 Romania Companion Diagnostics Market By Product & Service
14.3.2.8.2 Romania Companion Diagnostics Market By Technology
14.3.2.8.3 Romania Companion Diagnostics Market By Indication
14.3.2.8.4 Romania Companion Diagnostics Market By Sample Type
14.3.2.8.5 Romania Companion Diagnostics Market, By End User
14.3.2.9 Hungary
14.3.2.9.1 Hungary Companion Diagnostics Market By Product & Service
14.3.2.9.2 Hungary Companion Diagnostics Market By Technology
14.3.2.9.3 Hungary Companion Diagnostics Market By Indication
14.3.2.9.4 Hungary Companion Diagnostics Market By Sample Type
14.3.2.9.5 Hungary Companion Diagnostics Market, By End User
14.3.2.10 Turkey
14.3.2.10.1 Turkey Companion Diagnostics Market By Product & Service
14.3.2.10.2 Turkey Companion Diagnostics Market By Technology
14.3.2.10.3 Turkey Companion Diagnostics Market By Indication
14.3.2.10.4 Turkey Companion Diagnostics Market By Sample Type
14.3.2.10.5 Turkey Companion Diagnostics Market, By End User
14.3.2.11 Rest of Eastern Europe
14.3.2.11.1 Rest of Eastern Europe Companion Diagnostics Market By Product & Service
14.3.2.11.2 Rest of Eastern Europe Companion Diagnostics Market By Technology
14.3.2.11.3 Rest of Eastern Europe Companion Diagnostics Market By Indication
14.3.2.11.4 Rest of Eastern Europe Companion Diagnostics Market By Sample Type
14.3.2.11.5 Rest of Eastern Europe Companion Diagnostics Market, By End User
14.3.3 Western Europe
14.3.3.1 Western Europe Companion Diagnostics Market By Country
14.3.3.2 Western Europe Companion Diagnostics Market By Product & Service
14.3.3.3 Western Europe Companion Diagnostics Market By Technology
14.3.3.4 Western Europe Companion Diagnostics Market By Indication
14.3.3.5 Western Europe Companion Diagnostics Market By Sample Type
14.3.3.6 Western Europe Companion Diagnostics Market, By End User
14.3.3.7 Germany
14.3.3.7.1 Germany Companion Diagnostics Market By Product & Service
14.3.3.7.2 Germany Companion Diagnostics Market By Technology
14.3.3.7.3 Germany Companion Diagnostics Market By Indication
14.3.3.7.4 Germany Companion Diagnostics Market By Sample Type
14.3.3.7.5 Germany Companion Diagnostics Market, By End User
14.3.3.8 France
14.3.3.8.1 France Companion Diagnostics Market By Product & Service
14.3.3.8.2 France Companion Diagnostics Market By Technology
14.3.3.8.3 France Companion Diagnostics Market By Indication
14.3.3.8.4 France Companion Diagnostics Market By Sample Type
14.3.3.8.5 France Companion Diagnostics Market, By End User
14.3.3.9 UK
14.3.3.9.1 UK Companion Diagnostics Market By Product & Service
14.3.3.9.2 UK Companion Diagnostics Market By Technology
14.3.3.9.3 UK Companion Diagnostics Market By Indication
14.3.3.9.4 UK Companion Diagnostics Market By Sample Type
14.3.3.9.5 UK Companion Diagnostics Market, By End User
14.3.3.10 Italy
14.3.3.10.1 Italy Companion Diagnostics Market By Product & Service
14.3.3.10.2 Italy Companion Diagnostics Market By Technology
14.3.3.10.3 Italy Companion Diagnostics Market By Indication
14.3.3.10.4 Italy Companion Diagnostics Market By Sample Type
14.3.3.10.5 Italy Companion Diagnostics Market, By End User
14.3.3.11 Spain
14.3.3.11.1 Spain Companion Diagnostics Market By Product & Service
14.3.3.11.2 Spain Companion Diagnostics Market By Technology
14.3.3.11.3 Spain Companion Diagnostics Market By Indication
14.3.3.11.4 Spain Companion Diagnostics Market By Sample Type
14.3.3.11.5 Spain Companion Diagnostics Market, By End User
14.3.3.12 Netherlands
14.3.3.12.1 Netherlands Companion Diagnostics Market By Product & Service
14.3.3.12.2 Netherlands Companion Diagnostics Market By Technology
14.3.3.12.3 Netherlands Companion Diagnostics Market By Indication
14.3.3.12.4 Netherlands Companion Diagnostics Market By Sample Type
14.3.3.12.5 Netherlands Companion Diagnostics Market, By End User
14.3.3.13 Switzerland
14.3.3.13.1 Switzerland Companion Diagnostics Market By Product & Service
14.3.3.13.2 Switzerland Companion Diagnostics Market By Technology
14.3.3.13.3 Switzerland Companion Diagnostics Market By Indication
14.3.3.13.4 Switzerland Companion Diagnostics Market By Sample Type
14.3.3.13.5 Switzerland Companion Diagnostics Market, By End User
14.3.3.14 Austria
14.3.3.14.1 Austria Companion Diagnostics Market By Product & Service
14.3.3.14.2 Austria Companion Diagnostics Market By Technology
14.3.3.14.3 Austria Companion Diagnostics Market By Indication
14.3.3.14.4 Austria Companion Diagnostics Market By Sample Type
14.3.3.14.5 Austria Companion Diagnostics Market, By End User
14.3.3.15 Rest of Western Europe
14.3.3.15.1 Rest of Western Europe Companion Diagnostics Market By Product & Service
14.3.3.15.2 Rest of Western Europe Companion Diagnostics Market By Technology
14.3.3.15.3 Rest of Western Europe Companion Diagnostics Market By Indication
14.3.3.15.4 Rest of Western Europe Companion Diagnostics Market By Sample Type
14.3.3.15.5 Rest of Western Europe Companion Diagnostics Market, By End User
14.4 Asia-Pacific
14.4.1 Trend Analysis
14.4.2 Asia-Pacific Companion Diagnostics Market By country
14.4.3 Asia-Pacific Companion Diagnostics Market By Product & Service
14.4.4 Asia-Pacific Companion Diagnostics Market By Technology
14.4.5 Asia-Pacific Companion Diagnostics Market By Indication
14.4.6 Asia-Pacific Companion Diagnostics Market By Sample Type
14.4.7 Asia-Pacific Companion Diagnostics Market, By End User
14.4.8 China
14.4.8.1 China Companion Diagnostics Market By Product & Service
14.4.8.2 China Companion Diagnostics Market By Technology
14.4.8.3 China Companion Diagnostics Market By Indication
14.4.8.4 China Companion Diagnostics Market By Sample Type
14.4.8.5 China Companion Diagnostics Market, By End User
14.4.9 India
14.4.9.1 India Companion Diagnostics Market By Product & Service
14.4.9.2 India Companion Diagnostics Market By Technology
14.4.9.3 India Companion Diagnostics Market By Indication
14.4.9.4 India Companion Diagnostics Market By Sample Type
14.4.9.5 India Companion Diagnostics Market, By End User
14.4.10 Japan
14.4.10.1 Japan Companion Diagnostics Market By Product & Service
14.4.10.2 Japan Companion Diagnostics Market By Technology
14.4.10.3 Japan Companion Diagnostics Market By Indication
14.4.10.4 Japan Companion Diagnostics Market By Sample Type
14.4.10.5 Japan Companion Diagnostics Market, By End User
14.4.11 South Korea
14.4.11.1 South Korea Companion Diagnostics Market By Product & Service
14.4.11.2 South Korea Companion Diagnostics Market By Technology
14.4.11.3 South Korea Companion Diagnostics Market By Indication
14.4.11.4 South Korea Companion Diagnostics Market By Sample Type
14.4.11.5 South Korea Companion Diagnostics Market, By End User
14.4.12 Vietnam
14.4.12.1 Vietnam Companion Diagnostics Market By Product & Service
14.4.12.2 Vietnam Companion Diagnostics Market By Technology
14.4.12.3 Vietnam Companion Diagnostics Market By Indication
14.4.12.4 Vietnam Companion Diagnostics Market By Sample Type
14.4.12.5 Vietnam Companion Diagnostics Market, By End User
14.4.13 Singapore
14.4.13.1 Singapore Companion Diagnostics Market By Product & Service
14.4.13.2 Singapore Companion Diagnostics Market By Technology
14.4.13.3 Singapore Companion Diagnostics Market By Indication
14.4.13.4 Singapore Companion Diagnostics Market By Sample Type
14.4.13.5 Singapore Companion Diagnostics Market, By End User
14.4.14 Australia
14.4.14.1 Australia Companion Diagnostics Market By Product & Service
14.4.14.2 Australia Companion Diagnostics Market By Technology
14.4.14.3 Australia Companion Diagnostics Market By Indication
14.4.14.4 Australia Companion Diagnostics Market By Sample Type
14.4.14.5 Australia Companion Diagnostics Market, By End User
14.4.15 Rest of Asia-Pacific
14.4.15.1 Rest of Asia-Pacific Companion Diagnostics Market By Product & Service
14.4.15.2 Rest of Asia-Pacific Companion Diagnostics Market By Technology
14.4.15.3 Rest of Asia-Pacific Companion Diagnostics Market By Indication
14.4.15.4 Rest of Asia-Pacific Companion Diagnostics Market By Sample Type
14.4.15.5 Rest of Asia-Pacific Companion Diagnostics Market, By End User
14.5 Middle East & Africa
14.5.1 Trend Analysis
14.5.2 Middle East
14.5.2.1 Middle East Companion Diagnostics Market By Country
14.5.2.2 Middle East Companion Diagnostics Market By Product & Service
14.5.2.3 Middle East Companion Diagnostics Market By Technology
14.5.2.4 Middle East Companion Diagnostics Market By Indication
14.5.2.5 Middle East Companion Diagnostics Market By Sample Type
14.5.2.6 Middle East Companion Diagnostics Market, By End User
14.5.2.7 UAE
14.5.2.7.1 UAE Companion Diagnostics Market By Product & Service
14.5.2.7.2 UAE Companion Diagnostics Market By Technology
14.5.2.7.3 UAE Companion Diagnostics Market By Indication
14.5.2.7.4 UAE Companion Diagnostics Market By Sample Type
14.5.2.7.5 UAE Companion Diagnostics Market, By End User
14.5.2.8 Egypt
14.5.2.8.1 Egypt Companion Diagnostics Market By Product & Service
14.5.2.8.2 Egypt Companion Diagnostics Market By Technology
14.5.2.8.3 Egypt Companion Diagnostics Market By Indication
14.5.2.8.4 Egypt Companion Diagnostics Market By Sample Type
14.5.2.8.5 Egypt Companion Diagnostics Market, By End User
14.5.2.9 Saudi Arabia
14.5.2.9.1 Saudi Arabia Companion Diagnostics Market By Product & Service
14.5.2.9.2 Saudi Arabia Companion Diagnostics Market By Technology
14.5.2.9.3 Saudi Arabia Companion Diagnostics Market By Indication
14.5.2.9.4 Saudi Arabia Companion Diagnostics Market By Sample Type
14.5.2.9.5 Saudi Arabia Companion Diagnostics Market, By End User
14.5.2.10 Qatar
14.5.2.10.1 Qatar Companion Diagnostics Market By Product & Service
14.5.2.10.2 Qatar Companion Diagnostics Market By Technology
14.5.2.10.3 Qatar Companion Diagnostics Market By Indication
14.5.2.10.4 Qatar Companion Diagnostics Market By Sample Type
14.5.2.10.5 Qatar Companion Diagnostics Market, By End User
14.5.2.11 Rest of Middle East
14.5.2.11.1 Rest of Middle East Companion Diagnostics Market By Product & Service
14.5.2.11.2 Rest of Middle East Companion Diagnostics Market By Technology
14.5.2.11.3 Rest of Middle East Companion Diagnostics Market By Indication
14.5.2.11.4 Rest of Middle East Companion Diagnostics Market By Sample Type
14.5.2.11.5 Rest of Middle East Companion Diagnostics Market, By End User
14.5.3 Africa
14.5.3.1 Africa Companion Diagnostics Market By Country
14.5.3.2 Africa Companion Diagnostics Market By Product & Service
14.5.3.3 Africa Companion Diagnostics Market By Technology
14.5.3.4 Africa Companion Diagnostics Market By Indication
14.5.3.5 Africa Companion Diagnostics Market By Sample Type
14.5.3.6 Africa Companion Diagnostics Market, By End User
14.5.3.7 Nigeria
14.5.3.7.1 Nigeria Companion Diagnostics Market By Product & Service
14.5.3.7.2 Nigeria Companion Diagnostics Market By Technology
14.5.3.7.3 Nigeria Companion Diagnostics Market By Indication
14.5.3.7.4 Nigeria Companion Diagnostics Market By Sample Type
14.5.3.7.5 Nigeria Companion Diagnostics Market, By End User
14.5.3.8 South Africa
14.5.3.8.1 South Africa Companion Diagnostics Market By Product & Service
14.5.3.8.2 South Africa Companion Diagnostics Market By Technology
14.5.3.8.3 South Africa Companion Diagnostics Market By Indication
14.5.3.8.4 South Africa Companion Diagnostics Market By Sample Type
14.5.3.8.5 South Africa Companion Diagnostics Market, By End User
14.5.3.9 Rest of Africa
14.5.3.9.1 Rest of Africa Companion Diagnostics Market By Product & Service
14.5.3.9.2 Rest of Africa Companion Diagnostics Market By Technology
14.5.3.9.3 Rest of Africa Companion Diagnostics Market By Indication
14.5.3.9.4 Rest of Africa Companion Diagnostics Market By Sample Type
14.5.3.9.5 Rest of Africa Companion Diagnostics Market, By End User
14.6 Latin America
14.6.1 Trend Analysis
14.6.2 Latin America Companion Diagnostics Market By country
14.6.3 Latin America Companion Diagnostics Market By Product & Service
14.6.4 Latin America Companion Diagnostics Market By Technology
14.6.5 Latin America Companion Diagnostics Market By Indication
14.6.6 Latin America Companion Diagnostics Market By Sample Type
14.6.7 Latin America Companion Diagnostics Market, By End User
14.6.8 Brazil
14.6.8.1 Brazil Companion Diagnostics Market By Product & Service
14.6.8.2 Brazil Companion Diagnostics Market By Technology
14.6.8.3 Brazil Companion Diagnostics Market By Indication
14.6.8.4 Brazil Companion Diagnostics Market By Sample Type
14.6.8.5 Brazil Companion Diagnostics Market, By End User
14.6.9 Argentina
14.6.9.1 Argentina Companion Diagnostics Market By Product & Service
14.6.9.2 Argentina Companion Diagnostics Market By Technology
14.6.9.3 Argentina Companion Diagnostics Market By Indication
14.6.9.4 Argentina Companion Diagnostics Market By Sample Type
14.6.9.5 Argentina Companion Diagnostics Market, By End User
14.6.10 Colombia
14.6.10.1 Colombia Companion Diagnostics Market By Product & Service
14.6.10.2 Colombia Companion Diagnostics Market By Technology
14.6.10.3 Colombia Companion Diagnostics Market By Indication
14.6.10.4 Colombia Companion Diagnostics Market By Sample Type
14.6.10.5 Colombia Companion Diagnostics Market, By End User
14.6.11 Rest of Latin America
14.6.11.1 Rest of Latin America Companion Diagnostics Market By Product & Service
14.6.11.2 Rest of Latin America Companion Diagnostics Market By Technology
14.6.11.3 Rest of Latin America Companion Diagnostics Market By Indication
14.6.11.4 Rest of Latin America Companion Diagnostics Market By Sample Type
14.6.11.5 Rest of Latin America Companion Diagnostics Market, By End User
15. Company Profiles
15.1 Agilent Technologies, Inc.
15.1.1 Company Overview
15.1.2 Financial
15.1.3 Product & Services/ Services Offered
15.1.4 SWOT Analysis
15.1.5 The SNS View
15.2 Illumina, Inc.
15.2.1 Company Overview
15.2.2 Financial
15.2.3 Product & Services/ Services Offered
15.2.4 SWOT Analysis
15.2.5 The SNS View
15.3 QIAGEN N.V.
15.3.1 Company Overview
15.3.2 Financial
15.3.3 Product & Services/ Services Offered
15.3.4 SWOT Analysis
15.3.5 The SNS View
15.4 Thermo Fisher Scientific, Inc.
15.4.1 Company Overview
15.4.2 Financial
15.4.3 Product & Services/ Services Offered
15.4.4 SWOT Analysis
15.4.5 The SNS View
15.5 F. Hoffmann-La Roche Ltd.
15.5.1 Company Overview
15.5.2 Financial
15.5.3 Product & Services/ Services Offered
15.5.4 SWOT Analysis
15.5.5 The SNS View
15.6 ARUP Laboratories
15.6.1 Company Overview
15.6.2 Financial
15.6.3 Product & Services/ Services Offered
15.6.4 SWOT Analysis
15.6.5 The SNS View
15.7 Abbott
15.7.1 Company Overview
15.7.2 Financial
15.7.3 Product & Services/ Services Offered
15.7.4 SWOT Analysis
15.7.5 The SNS View
15.8 Myriad Genetics, Inc.
15.8.1 Company Overview
15.8.2 Financial
15.8.3 Product & Services/ Services Offered
15.8.4 SWOT Analysis
15.8.5 The SNS View
15.9 bioMérieux SA
15.9.1 Company Overview
15.9.2 Financial
15.9.3 Product & Services/ Services Offered
15.9.4 SWOT Analysis
15.9.5 The SNS View
15.10 Invivoscribe, Inc.
15.10.1 Company Overview
15.10.2 Financial
15.10.3 Product & Services/ Services Offered
15.10.4 SWOT Analysis
15.10.5 The SNS View
16. Competitive Landscape
16.1 Competitive Benchmarking
16.2 Market Share Analysis
16.3 Recent Developments
16.3.1 Industry News
16.3.2 Company News
16.3.3 Mergers & Acquisitions
17. Use Case and Best Practices
18. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Molecular Modeling Market Size was valued at USD 5.61 billion in 2023 and is expected to reach USD 14.08 billion by 2031 and grow at a CAGR of 12.2% over the forecast period 2024-2031.
The Vitamin D Testing Market Size was valued at USD 31.5 billion in 2023 and reach USD 47.32 billion by 2031 growing at a CAGR of 5.2% from 2024 to 2031.
The Medical Ceramics Market size was estimated at USD 20.2 billion in 2023 and is expected to reach USD 30.09 billion By 2031 at a CAGR of 5.11% during the forecast period of 2024-2031.
The Patient Registry Software Market Size was evaluated at USD 16.79 billion in 2023, and is predicted to increase at a CAGR of 9.7% from 2024 to 2031, to reach USD 35.23 billion by 2031.
The Antiperspirants and Deodorants Market Size was valued at USD 62,889 million in 2023 and is expected to reach USD 81,920.89 million by 2031, and grow at a CAGR of 3.36% over the forecast period 2024-2031.
The Dental Implants Market size was estimated at USD 4.98 billion in 2023 and is expected to reach USD 10.59 billion by 2031 with a growing CAGR of 9.9% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
